Advocacy

We raise patient voices to increase awareness about ALS and its impact, and work tenaciously to target and inform policy, process, support, and funding change.

Bringing the ALS Patient Perspective to Canada’s Drug Policy Reform Debate

ALS Action Canada Member Dr. Andrew Darke, who is living with ALS, is contributing to the national debate on drug policy reform. In a Financial Post commentary with Nigel Rawson and John Adams, he examines how recent U.S. trade policies strengthen the case for reforms to Canada’s drug approval, pricing and coverage processes. For ALS Action Canada, advocating for timely and equitable access to innovative treatments remains a key priority.

Read More »

A Missed Opportunity: ALS Research Funding Absent from the 2026 Federal Budget

ALS Action Canada is deeply disappointed that the 2026 federal budget failed to include a proposed $50 million investment in ALS research over five years. Following our advocacy efforts on Parliament Hill alongside coalition partners, we continue calling for meaningful federal action to accelerate progress toward effective treatments and a cure.

Read More »

A Patient Perspective on ALS Clinical Trials and Timely Access

How much evidence should be required before people living with ALS can access a promising new therapy?

In a newly published Reader Response in Neurology, Dr. Andrew Darke, an ALS Action Canada Advocacy Committee Member, responds to a recent article examining what its authors describe as a “credibility gap” in ALS clinical trials, due to what it describes as a “Clinical Trial Industrial Complex” involving ALS neurologists and manufacturers of new drugs for ALS.

Read More »

Challenging Barriers to ALS Treatment Access: Bringing Our Patient Voice to Canada’s Drug Agency

From time to time, we hear of pALS who are not eligible to get Radicava under their provincial or private insurance plan. Recently we heard of a pALS who had been on Radicava, but were later told they were no longer eligible to receive it. The reason for this is the criteria for who is eligible for drugs, and who can continue to receive them under the provincial drug benefit plans. These criteria are developed by Canada’s Drug Agency (CDA), which is a separate agency from Health Canada which approves drugs as safe and effective
to be marketed.

Read More »

Examining the Impact of U.S. Drug Pricing Pressure on Canada

ALS Action Canada Advocacy Committee member Dr. Andrew Darke co-authored a Financial Post commentary examining how U.S. drug pricing pressure could affect Canada’s pharmaceutical landscape, investment and access to innovative treatments, including therapies for people living with ALS.

Read More »

Patient Perspectives Highlight Importance of Modest ALS Treatment Gains 

Recent pieces published in the international neurology journal, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, have sparked debate in the ALS community. 

In ALS Action Canada’s paper (Darke and Orsulak 2025), “How Effective Does a New Drug for Amyotrophic Lateral Sclerosis Need To Be – The Patient Perspective”, we argued against the proposal of Boddy et al (2025).

Read More »

Canadian Collaboration to End ALS 

This coordinated day of action, spearheaded by ALS Canada, had representation from 41 ridings and included meetings with 23 MPs and Senators. Notably, nine MPs heard directly from the ALS community for the first time, underscoring the importance of this collective. The Canadian Collaboration to End ALS joined together for

Read More »